Report Categories
View AllRecent Articles
View All
OVID Ovid Therapeutics swings to profit with 1181 revenue jump defying biotech sector headwinds in Q4 2025
What downside volume Guardant Health GH 035 20260429
MFAC MFA latest quarterly earnings report has no available consensus EPS or revenue forecasts for comparison
ERNAW Ernexa to share quarterly earnings context and updated clinical pipeline progress with investors this month